) Since its origin in Fall 1996, the Pharmacology Core has steadily grown into being an important CCC resource for several investigators. Its mission is providing expertise in pharmacological sciences, including kinetics, dynamics, biopharmaceutics and physical pharmacy. Pharmacokinetic support includes drug absorption, metabolism, distribution, elimination, bioactivation and drug-drug interactions. Pharmacodynamic support includes molecular effects of drug exposure, and in vitro toxicity testing. Biopharmaceutic support includes the influence of dose and dosage form on pharmacokinetics. Physical pharmacy support includes production of (approximate dose) prototype forms of drugs for preclinical studies and clinical forms for IND studies. Enhancements of research by the Core take the form of study design, data acquisition, data analysis, and interpretation of results, including technical writing for manuscripts and grant proposals written by CCC investigators. This core also developed and oversees the Quality Assurance Plan for tracking and handling clinical pharmacology specimens throughout the Institute. Key features of this Core are the scope of services provided, its integral role in clinical specimen handling, existing collegial relationships, direct consultation for requesting investigators, and the interests and commitment of its staff. Pharmacological contributions benefited 5 Programs, including Developmental Therapeutics, Breast Cancer, Molecular Biology and Genetics, Prostate Cancer and Protease Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-22S1
Application #
6503921
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-09-27
Project End
2001-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164
Eggly, Susan; Hamel, Lauren M; Foster, Tanina S et al. (2017) Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. Patient Educ Couns 100:818-826
Bao, Bin; Mitrea, Cristina; Wijesinghe, Priyanga et al. (2017) Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep 7:44125
Bernardo, Margarida M; Dzinic, Sijana H; Matta, Maria J et al. (2017) The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. J Cell Biochem 118:1639-1647
Soave, Claire L; Guerin, Tracey; Liu, Jinbao et al. (2017) Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev 36:717-736
Jones, Carissa C; Bush, William S; Crawford, Dana C et al. (2017) Germline Genetic Variants and Lung Cancer Survival in African Americans. Cancer Epidemiol Biomarkers Prev 26:1288-1295
Bosnyák, Edit; Michelhaugh, Sharon K; Klinger, Neil V et al. (2017) Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. Clin Nucl Med 42:341-347
Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323
Tan, Zhijing; Nie, Song; McDermott, Sean P et al. (2017) Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. J Proteome Res 16:842-851
Embogama, D Maheeka; Pflum, Mary Kay H (2017) K-BILDS: A Kinase Substrate Discovery Tool. Chembiochem 18:136-141

Showing the most recent 10 out of 726 publications